NJEDA
VC Fund
Newark, United States
NJEDA is a government entity assisting and giving access to capital, including tax-exempt and taxable bond financing. It also offers loans, loan guarantees, and business and tax incentives. In addition, it offers real estate development assistance and technology facilities. In 1974, John Smith established it in Trenton, New Jersey.
- Total investments:
- 143
- Last investment:
- Lead investor:
- 89%
- Fund size:
- $3M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries NJEDA invests in
Stages NJEDA invests in
Countries NJEDA invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 12 contacts → | |||
Investment Focus
Industry
- Health Care 20 (14%)
- Biotechnology 15 (10%)
- Medical 12 (8%)
- Information Technology 10 (7%)
- Software 9 (6%)
Stage
- Grant 90 (63%)
- Seed 7 (5%)
- Venture - Series Unknown 5 (3%)
- Funding Round 4 (3%)
- Series A 3 (2%)
Country
- United States 98 (69%)
- Trinidad and Tobago 3 (2%)
- Israel 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Frederick J. Cole
Senior Vice President- Operations
|
Senior Vice President- Operations | Total investments: 0 | Find email | |
Lori Matheus
Senior Vice President- Finance & Development
|
Senior Vice President- Finance & Development | Total investments: 0 | Find email | |
Debbie Hart
Chair at the Commission on Science, Innovation and Technology (CSIT)
|
Chair at the Commission on Science, Innovation and Technology (CSIT) | Total investments: 12 | Find email | |
Emma Corrado
Deputy Chief Operating Officer
|
Deputy Chief Operating Officer | Total investments: 0 | Find email | |
Evan Weiss
President and CEO
|
President and CEO | Total investments: 0 | Find email | |
| See all 12 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| PureLi is a cleantech company that boosts lithium extraction and production from brine sources. | $5M / Grant / Aug 12, 2026 | ||
| We develops software for clinical trial operations. Its platform, TriClick, uses AI agents to assist with tasks such as data anonymization, protocol design, and patient recruitment. The tools extract information from medical records, generate standardized reports, and organize content for regulatory submissions. They integrate with clinical datasystems and follow data privacy requirements. The company’s team includes professionals in artificial intelligence and clinical research. | Venture - Series Unknown / Jul 01, 2026 | ||
| CardioLink AI uses AI to improve cardiac patient care. Their platform automates ECG analysis and identifies high-risk cardiovascular conditions early, helping doctors make faster, more accurate diagnoses. By streamlining clinical workflows and providing real-time insights, they aim to reduce hospital readmissions and improve patient outcomesthrough advanced, data-driven heart monitoring. | Grant / Apr 07, 2026 | ||
| AIntropy develops "Universal Knowledge Perception" technology, enabling AI to retrieve and understand information from multi-modal sources like video, visual data, and databases. This platform supports high-value applications, including real-time sales copilots and pharmaceutical compliance | Grant / Apr 06, 2026 | ||
| AgentGov provides an AI-powered fraud detection platform designed for government, utilizing advanced algorithms to identify anomalies and generate court-ready evidence | Grant / Apr 06, 2026 | ||
|
DevPlus
|
DevPlus is an AI-agent infrastructure management with embedded compliance | Grant / Apr 06, 2026 | |
|
GlucoSync
|
GlucoSync is a real-time AI decision support for diabetes treatment | Grant / Apr 06, 2026 | |
| Hydronos Labs is the “Weather Underground” for near-term weather and climate hazard risk - a broadly available, scientifically credible platform, providing a continuously improving underlying data and software layer. Founded by lead scientist Colby Fisher PhD and Princeton Executive-in-Residence Joseph Studholme in 2020, Hydronos has built anext-generation “insights-as-a-service” platform - superior in cost, transparency and ease of use. Successful POCs from the platform include flood history underwriting, disaster emergency response, and wildfire risk to inventory/pricing/delivery for a national supermarket retail supply chain.In September 2024, Hydronos was selected (14 companies out of 700+) for the prestigious NJ FAST Plug&Play accelerator program.This is an ‘‘Open Core” product model: leveraging a robust research user community to improve and monetize current and future edges in data/model quality - through AI, machine learning, and knowledge graph powered software products provided via a freemium model. Our goal is to establish Hydronos Labs as the primary “open” provider of this layer in the risk transfer financial ecosystem - as the branded, trusted, broadly available, reasonably priced global data platform for commercially actionable climate intelligence. From a broad user base, we build credibility, a customer-driven development cycle and a brand that will enable proven monetization strategies at scale, including marketing to qualified users of mitigation and insurance partner solutions for their identified risks. | Grant / Apr 06, 2026 | ||
|
Scholera
|
Scholera is an adaptive, predictive learning intelligence platform | Grant / Apr 06, 2026 | |
| Citius Pharmaceuticals is a biopharmaceutical company that develops and commercializes therapeutic products for large and growing markets. Citius products offer new and expanded indications for previously approved pharmaceutical products as a means to achieve market position or market exclusivity. By using previously approved drugs withsubstantial safety and efficacy data, Citius seeks to reduce the risks associated with pharmaceutical product development.Citius is advancing two proprietary product candidates, our Mino-Lok™ product and a Hydrocortisone-Lidocaine formulation. Citius believes the markets for its products are large and underserved by the current standard of care. | $3.8M / Grant / Feb 24, 2026 | ||
| See all 143 investments → | |||
Co-Investors
Commission on Science, Innovation and Technology
12 deals together
New Jersey Economic Development Authority
3 deals together
SOSV HAX
2 deals together
ARPA-E
1 deal together
Broadfin Capital
1 deal together
Cabinet Office - GOV.UK
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does NJEDA invest in?
NJEDA invests primarily in Health Care, Biotechnology and Medical startups, most often at Grant and Seed stage. Most of the 143 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact NJEDA?
Public channels for NJEDA include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at NJEDA?
The team at NJEDA includes Frederick J. Cole (Senior Vice President- Operations), Lori Matheus (Senior Vice President- Finance & Development) and Debbie Hart (Chair at the Commission on Science, Innovation and Technology (CSIT)), among 12 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
